Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Methotrexate (Primary) ; Tacrolimus (Primary) ; Tocilizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 16 Oct 2018 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.